X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4404) 4404
Publication (265) 265
Book Review (24) 24
Magazine Article (6) 6
Book / eBook (5) 5
Book Chapter (3) 3
Conference Proceeding (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (2375) 2375
male (2374) 2374
humans (2366) 2366
isoquinolines - pharmacology (2042) 2042
female (1468) 1468
rats (1329) 1329
index medicus (1260) 1260
isoquinolines - administration & dosage (1097) 1097
adult (1036) 1036
middle aged (915) 915
pharmacology & pharmacy (902) 902
isoquinolines - therapeutic use (810) 810
dose-response relationship, drug (637) 637
mice (637) 637
aged (604) 604
neurosciences (570) 570
tetrahydroisoquinolines (527) 527
time factors (466) 466
rats, sprague-dawley (434) 434
isoquinolines - pharmacokinetics (412) 412
isoquinolines - metabolism (396) 396
isoquinolines - adverse effects (391) 391
anesthesiology (334) 334
adolescent (318) 318
isoquinolines (316) 316
oncology (311) 311
rats, wistar (305) 305
isoquinolines - chemistry (271) 271
biochemistry & molecular biology (259) 259
drug therapy, combination (246) 246
blood pressure - drug effects (238) 238
atracurium (231) 231
sulfonamides - pharmacology (223) 223
mivacurium (222) 222
in vitro techniques (221) 221
administration, oral (216) 216
double-blind method (216) 216
analysis (206) 206
disease models, animal (206) 206
brain (202) 202
treatment outcome (197) 197
medicine & public health (195) 195
neuromuscular nondepolarizing agents - administration & dosage (193) 193
cells, cultured (192) 192
pharmacokinetics (190) 190
cancer (185) 185
rats, inbred strains (185) 185
chemistry, medicinal (184) 184
enzyme inhibitors - pharmacology (181) 181
palonosetron (181) 181
brain - metabolism (177) 177
drug administration schedule (177) 177
drug interactions (175) 175
child (173) 173
vomiting - chemically induced (173) 173
expression (170) 170
rat (170) 170
quinuclidines - therapeutic use (167) 167
nausea - chemically induced (163) 163
isoquinolines - blood (160) 160
kinetics (159) 159
antineoplastic agents - adverse effects (158) 158
chemotherapy (153) 153
quinapril (153) 153
heart rate - drug effects (150) 150
activation (149) 149
dogs (149) 149
in-vitro (148) 148
antiemetics - therapeutic use (147) 147
structure-activity relationship (147) 147
vomiting - prevention & control (147) 147
neuromuscular nondepolarizing agents - pharmacology (145) 145
anesthesia (143) 143
apoptosis (142) 142
pharmacology (140) 140
inhibition (137) 137
nausea - prevention & control (136) 136
cyclic amp-dependent protein kinases - antagonists & inhibitors (134) 134
double-blind (134) 134
neuromuscular junction - drug effects (132) 132
infusions, intravenous (129) 129
health aspects (128) 128
nausea (128) 128
quinuclidines - administration & dosage (128) 128
alkaloids - pharmacology (127) 127
research (127) 127
sulfonamides - administration & dosage (127) 127
cells (126) 126
in-vivo (126) 126
piperazines - pharmacology (126) 126
care and treatment (125) 125
injections, intravenous (125) 125
rabbits (125) 125
brain - drug effects (122) 122
endocrinology & metabolism (121) 121
alkaloids (120) 120
prevention (120) 120
clinical trials as topic (119) 119
mice, inbred c57bl (119) 119
article (118) 118
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4219) 4219
German (41) 41
French (36) 36
Japanese (28) 28
Spanish (25) 25
Russian (20) 20
Italian (13) 13
Chinese (10) 10
Portuguese (8) 8
Bulgarian (6) 6
Czech (3) 3
Danish (3) 3
Polish (3) 3
Hungarian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | PREVENTION | APREPITANT | PROPHYLAXIS | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | INDUCED EMESIS | CISPLATIN | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 07/2014, Volume 12, Issue 7, pp. 763 - 773
About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver... 
interferon-free | ledipasvir | sofosbuvir | MK-8742 | ombitasvir | MK-5172 | ABT-450 | asunaprevir | dasabuvir | daclatasvir | Daclatasvir | Ombitasvir | Interferon-free | Ledipasvir | Asunaprevir | Sofosbuvir | Dasabuvir | CONTROLLED-TRIAL | PLUS RIBAVIRIN | LIVER-TRANSPLANTATION | HCV INFECTION | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | TREATMENT OPTIONS | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | CHRONIC VIRAL-HEPATITIS | DISEASE PROGRESSION | Uridine Monophosphate - administration & dosage | Quinoxalines - adverse effects | Anilides - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Carbamates - administration & dosage | Uracil - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Hepatitis C - prevention & control | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Disease Eradication | Benzofurans - therapeutic use | Quinoxalines - administration & dosage | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Anilides - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Carbamates - adverse effects | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Hepacivirus | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 3, pp. 490 - 499
Journal Article
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 1, pp. 30 - 37
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 05/2015, Volume 313, Issue 17, pp. 1736 - 1744
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 05/2015, Volume 313, Issue 17, pp. 1728 - 1735
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Journal Article
Journal Article
Journal Article